Mumbai-based Lupin announced it has received final approval from the U.S. FDA for its generic version of Lep Pharmaceutical Products’ Dovonex scalp solution.
Lupin's calcipotriene topical treatment is used to treat chronic, moderately severe psoriasis of the scalp.
According to the company, Lupin is the 8th largest generics pharmaceutical company by market capitalization and 6th largest generics pharmaceutical company by revenues.
Read the press release
